secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001601830-25-000126
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates
---------------------------------------------------------------------------

- Announced $7 million milestone from Sanofi partnership for partnered discovery program.
- REC-1245 (RBM39) DAHLIA Phase 1/2 trial enrolling patients with tumors exhibiting replication stress and DDR vulnerabilities.
- REC-617 (CDK7 inhibitor) combination cohort to target platinum-resistant ovarian cancer using multi-omic and causal AI.
- Co-founder and CEO Chris Gibson highlighted platform advancements including Boltz-2 for ligand design.
- Exhibit text truncated; specific Q2 revenue, EPS, and cash position figures were not provided in the available excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/0001601830-25-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/rxrx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer